Comparative estimation of domestic drugs Laifferon and Reaferon-ES antiviral treatment of the chronic viral hepatitis patients

The paper presents the results of clinical tests of the comparative estimation of tolerance, effectiveness and clinic-laboratory indices of chronic HBV and HCV patients Laifferon and Reaferon-ES treatment within a year (12 month). Less collateral effect caused by laifferon is stated. The results of...

Full description

Saved in:
Bibliographic Details
Main Authors: Ye. I. Petrova, K. I. Chuikova
Format: Article
Language:English
Published: Siberian State Medical University (Tomsk) 2009-08-01
Series:Бюллетень сибирской медицины
Subjects:
Online Access:https://bulletin.ssmu.ru/jour/article/view/1938
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849403244876398592
author Ye. I. Petrova
K. I. Chuikova
author_facet Ye. I. Petrova
K. I. Chuikova
author_sort Ye. I. Petrova
collection DOAJ
description The paper presents the results of clinical tests of the comparative estimation of tolerance, effectiveness and clinic-laboratory indices of chronic HBV and HCV patients Laifferon and Reaferon-ES treatment within a year (12 month). Less collateral effect caused by laifferon is stated. The results of effectiveness of Laifferon and Reaferon-ES treatment of the chronic HBV and HCV patients did not differ in compared groups.
format Article
id doaj-art-d76eb294c12f453b95118d8869f9ba28
institution Kabale University
issn 1682-0363
1819-3684
language English
publishDate 2009-08-01
publisher Siberian State Medical University (Tomsk)
record_format Article
series Бюллетень сибирской медицины
spelling doaj-art-d76eb294c12f453b95118d8869f9ba282025-08-20T03:37:19ZengSiberian State Medical University (Tomsk)Бюллетень сибирской медицины1682-03631819-36842009-08-0184(2)14715310.20538/1682-0363-2009-4(2)-147-1531430Comparative estimation of domestic drugs Laifferon and Reaferon-ES antiviral treatment of the chronic viral hepatitis patientsYe. I. Petrova0K. I. Chuikova1Сибирский государственный медицинский университетСибирский государственный медицинский университетThe paper presents the results of clinical tests of the comparative estimation of tolerance, effectiveness and clinic-laboratory indices of chronic HBV and HCV patients Laifferon and Reaferon-ES treatment within a year (12 month). Less collateral effect caused by laifferon is stated. The results of effectiveness of Laifferon and Reaferon-ES treatment of the chronic HBV and HCV patients did not differ in compared groups.https://bulletin.ssmu.ru/jour/article/view/1938chronic viral hepatitislaifferonreaferon-eseffectivenesstolerance
spellingShingle Ye. I. Petrova
K. I. Chuikova
Comparative estimation of domestic drugs Laifferon and Reaferon-ES antiviral treatment of the chronic viral hepatitis patients
Бюллетень сибирской медицины
chronic viral hepatitis
laifferon
reaferon-es
effectiveness
tolerance
title Comparative estimation of domestic drugs Laifferon and Reaferon-ES antiviral treatment of the chronic viral hepatitis patients
title_full Comparative estimation of domestic drugs Laifferon and Reaferon-ES antiviral treatment of the chronic viral hepatitis patients
title_fullStr Comparative estimation of domestic drugs Laifferon and Reaferon-ES antiviral treatment of the chronic viral hepatitis patients
title_full_unstemmed Comparative estimation of domestic drugs Laifferon and Reaferon-ES antiviral treatment of the chronic viral hepatitis patients
title_short Comparative estimation of domestic drugs Laifferon and Reaferon-ES antiviral treatment of the chronic viral hepatitis patients
title_sort comparative estimation of domestic drugs laifferon and reaferon es antiviral treatment of the chronic viral hepatitis patients
topic chronic viral hepatitis
laifferon
reaferon-es
effectiveness
tolerance
url https://bulletin.ssmu.ru/jour/article/view/1938
work_keys_str_mv AT yeipetrova comparativeestimationofdomesticdrugslaifferonandreaferonesantiviraltreatmentofthechronicviralhepatitispatients
AT kichuikova comparativeestimationofdomesticdrugslaifferonandreaferonesantiviraltreatmentofthechronicviralhepatitispatients